Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables (2016 - 2020)

Historic Notes Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Q3 2020 value amounting to $4.7 million.

  • Viridian Therapeutics, Inc.\DE's Notes Payables fell 4900.88% to $4.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $4.7 million, marking a year-over-year decrease of 4900.88%. This contributed to the annual value of $4.0 million for FY2019, which is 6139.06% down from last year.
  • Viridian Therapeutics, Inc.\DE's Notes Payables amounted to $4.7 million in Q3 2020, which was down 4900.88% from $3.4 million recorded in Q2 2020.
  • Viridian Therapeutics, Inc.\DE's Notes Payables' 5-year high stood at $10.3 million during Q4 2018, with a 5-year trough of $1.1 million in Q1 2016.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Notes Payables had a median value of $4.7 million in 2020 and averaged $5.9 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Notes Payables soared by 33339.37% in 2016, and later plummeted by 6706.93% in 2019.
  • Viridian Therapeutics, Inc.\DE's Notes Payables (Quarter) stood at $4.8 million in 2016, then skyrocketed by 107.18% to $9.9 million in 2017, then increased by 3.79% to $10.3 million in 2018, then tumbled by 61.39% to $4.0 million in 2019, then rose by 18.39% to $4.7 million in 2020.
  • Its Notes Payables was $4.7 million in Q3 2020, compared to $3.4 million in Q2 2020 and $7.4 million in Q1 2020.